News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
102,001 Results
Type
Article (6275)
Company Profile (20)
Press Release (95706)
Section
Business (30748)
Career Advice (199)
Deals (4754)
Drug Delivery (5)
Drug Development (8917)
Employer Resources (11)
FDA (2882)
Job Trends (2929)
News (49607)
Policy (5451)
Tag
2024 BioCapital Digital (1)
2024 BioMidwest Digital (2)
2024 Bio NC Digital (3)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Standard (1)
2025 Lone Star Bio Digital (1)
Academia (662)
Academic (1)
Allergies (14)
Alliances (9934)
ALS (6)
Alzheimer's disease (184)
Antibody-drug conjugate (ADC) (13)
Approvals (2923)
Artificial intelligence (33)
Automation (8)
Bankruptcy (26)
Best Places to Work (2268)
BIOSECURE Act (1)
Biosimilars (5)
Biotechnology (14)
Bladder cancer (10)
Brain cancer (4)
Breast cancer (47)
Cancer (339)
Cardiovascular disease (20)
Career advice (183)
Career pathing (1)
CAR-T (21)
Cell therapy (47)
Cervical cancer (9)
Clinical research (6911)
Collaboration (142)
Compensation (2)
Complete response letters (3)
COVID-19 (549)
CRISPR (5)
C-suite (19)
Cystic fibrosis (7)
Data (283)
Depression (1)
Diabetes (22)
Diagnostics (3153)
Digital health (1)
Diversity, equity & inclusion (1)
Drug discovery (19)
Drug pricing (2)
Drug shortages (1)
Duchenne muscular dystrophy (8)
Earnings (8833)
Employer branding (3)
Employer resources (9)
Events (10196)
Executive appointments (98)
FDA (3024)
Featured Employer (4)
Frontotemporal dementia (1)
Funding (75)
Gene editing (7)
Generative AI (3)
Gene therapy (33)
GLP-1 (102)
Government (896)
Grass and pollen (3)
Guidances (5)
Healthcare (2250)
Immunology and inflammation (3)
Indications (3)
Infectious disease (576)
Inflammatory bowel disease (7)
Influenza (12)
Intellectual property (10)
Interviews (24)
IPO (1411)
Job creations (773)
Job search strategy (174)
Kidney cancer (1)
Labor market (2)
Layoffs (31)
Leadership (1)
Legal (1112)
Liver cancer (8)
Lung cancer (60)
Lymphoma (25)
Machine learning (1)
Management (3)
Manufacturing (47)
MASH (3)
Medical device (1360)
Medtech (1360)
Mergers & acquisitions (3412)
Metabolic disorders (42)
Multiple sclerosis (3)
NASH (1)
Neurodegenerative disease (11)
Neuropsychiatric disorders (1)
Neuroscience (219)
NextGen: Class of 2025 (791)
Non-profit (578)
Northern California (235)
Now hiring (11)
Obesity (18)
Opinion (14)
Ovarian cancer (4)
Pain (5)
Pancreatic cancer (7)
Parkinson's disease (14)
Partnered (4)
Patents (16)
Patient recruitment (5)
Peanut (9)
People (9290)
Pharmaceutical (6)
Phase I (2033)
Phase II (2660)
Phase III (2683)
Pipeline (129)
Podcasts (1)
Policy (2)
Postmarket research (392)
Preclinical (1182)
Press Release (18)
Prostate cancer (20)
Psychedelics (2)
Radiopharmaceuticals (29)
Rare diseases (30)
Real estate (1965)
Recruiting (4)
Regulatory (3735)
Reports (7)
Research institute (631)
Resumes & cover letters (19)
RSV (3)
Series A (10)
Series B (7)
Sickle cell disease (5)
Southern California (243)
Spinal muscular atrophy (34)
Sponsored (6)
Startups (601)
State (1)
Stomach cancer (2)
Supply chain (9)
Tariffs (1)
The Weekly (1)
United States (2580)
Vaccines (49)
Venture capitalists (1)
Webinars (1)
Weight loss (11)
Women's health (3)
Date
Today (9)
Last 7 days (56)
Last 30 days (287)
Last 365 days (4048)
2025 (951)
2024 (4374)
2023 (5218)
2022 (8518)
2021 (8914)
2020 (8709)
2019 (6071)
2018 (4718)
2017 (5134)
2016 (5243)
2015 (5786)
2014 (4662)
2013 (4139)
2012 (4394)
2011 (4467)
2010 (3986)
Location
Africa (124)
Alabama (10)
Alaska (1)
Arizona (33)
Arkansas (2)
Asia (6299)
Australia (1063)
California (591)
Canada (236)
China (28)
Colorado (34)
Connecticut (29)
Delaware (25)
Europe (13767)
Florida (83)
Georgia (10)
Idaho (5)
Illinois (38)
India (3)
Indiana (37)
Iowa (2)
Japan (17)
Kansas (21)
Kentucky (4)
Louisiana (1)
Maine (24)
Maryland (100)
Massachusetts (378)
Michigan (56)
Minnesota (31)
Missouri (33)
Montana (9)
Nebraska (3)
Nevada (3)
New Hampshire (7)
New Jersey (265)
New Mexico (8)
New York (199)
North Carolina (143)
North Dakota (1)
Northern California (235)
Ohio (37)
Oklahoma (3)
Oregon (3)
Pennsylvania (110)
Rhode Island (10)
South America (176)
South Carolina (3)
Southern California (243)
Tennessee (17)
Texas (154)
Utah (40)
Virginia (11)
Washington D.C. (4)
Washington State (79)
Wisconsin (9)
102,001 Results for "frontage laboratories".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Frontage Laboratories and Medicover Integrated Clinical Services Announce Strategic Collaboration to Expand Global Genomic Testing Services
November 13, 2024
·
2 min read
Deals
Frontage Laboratories Acquires Accelera S.r.l.'s Bioanalytical and DMPK Businesses
Frontage Laboratories, Inc. today announced that, through its wholly-owned subsidiary Frontage Europe S.r.l., it has completed the acquisition of the Bioanalytical and Drug Metabolism & Pharmacokinetics businesses of Accelera S.r.l (Accelera).
January 2, 2024
·
5 min read
Deals
Frontage Acquires Nucro-Technics Inc. and Nucro-Technics Holdings, Inc.
Frontage Laboratories, Inc. and its wholly-owned subsidiary, Frontage Canada, Inc., completed the acquisition of Nucro-Technics Inc. and its affiliate Nucro-Technics Holdings, Inc.
August 16, 2023
·
3 min read
Deals
Frontage Laboratories Inc. Acquires Frontage Clinical Services Inc.
Frontage Laboratories, Inc. completed the acquisition of Frontage Clinical Services Inc., a clinical Phase I-IIa business located in Secaucus, NJ. Frontage Clinical provides a complete suite of services from study design to the delivery of final reports.
August 2, 2022
·
2 min read
Pharm Country
Frontage Announces Opening of Custom-Built State-of-the-Art Laboratory Facility in Hayward, CA
Frontage Laboratories, Inc. is pleased to announce the opening of a custom-built 19,000 square foot laboratory located at 3801 Bay Center Place, Hayward California.
September 21, 2022
·
2 min read
Deals
Frontage Laboratories, Inc. to Acquire Quintara Discovery, Inc.
Frontage Holdings Corporation (“Frontage” or the “Group”, 1521.HK), today announced that its wholly-owned subsidiary, Frontage Laboratories, Inc. (“Frontage Labs”), has entered into a definitive agreement for the acquisition of Quintara Discovery, Inc., (“Quintara”).
June 28, 2021
·
3 min read
Pharm Country
Frontage Laboratories, Inc is a PanaBIOS Trusted Travel Approved COVID-19 Laboratory Testing Provider
Frontage Laboratories, Inc is a PanaBIOS Trusted Travel Approved COVID-19 Laboratory Testing Provider.
September 9, 2021
·
1 min read
Business
Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference
Telomir Pharmaceuticals, Inc. today announced that Telomir, alongside its partner Frontage Laboratories, presented a scientific poster at the National University Health System of Singapore (NUHS) Centre for Healthy Longevity Conference 2024.
March 7, 2024
·
6 min read
Pharm Country
Frontage Expands Toxicology Services Through the Acquisition of Experimur
Frontage Laboratories, Inc. announced the acquisition of Experimur LLC and its affiliate Experimur Properties LLC.
January 11, 2022
·
3 min read
Drug Development
Frontage Partners with Eisai and Biogen to Complete the Clarity AD study for the Alzheimer’s Drug, Lecanemab
Frontage’s Bioanalytical team partnered with Eisai/Biogen to support the PK and PD biomarker bioanalysis of lecanemab (BAN2401) in their investigational global phase 3 study in US and China.
December 12, 2022
·
2 min read
1 of 10,201
Next
